Yoshida 2005.

Methods	Randomised clinical trial
Participants	Country: Canada Period of recruitment: not stated Number randomised: 148 Post‐randomisation dropouts: 0 (0.0%) Revised sample size: 148 Average age (years): 53 Females: 48 (32.4%) Primary transplantation: 148 (100.0%) Reason for transplantation Alcohol‐related cirrhosis: 29 (19.6%) Viral‐related cirrhosis: 56 (37.8%) Autoimmune disease‐related cirrhosis: 34 (23.0%) HCC: not stated Others: 29 (19.6%) Maintenance immunosuppression used during induction immunosuppression: tacrolimus plus mycophenolate mofetil Altered immunosuppression after withdrawal: no Other exclusion criteria: living donor liver transplant ABO blood group incompatibility multiple organ transplant serum creatinine > 180 micromol/L or dialysis fulminant liver failure
Interventions	Group 1: daclizumab + glucocorticosteroids (n = 72) Further details: daclizumab 2 mg/kg i.v. within 4 hours postoperatively and 1 mg/kg i.v. on postoperative day 4 + methylprednisolone 500 mg i.v. intraoperatively, tapering to 20 mg i.v. on postoperative day 5 followed by prednisone 5 mg/day orally. The prednisone was then tapered by 5 mg/month until discontinuation after the month 3 post‐transplant Group 2: glucocorticosteroids (n = 76) Further details: methylprednisolone 500 mg i.v. intraoperatively, tapering to 20 mg i.v. on postoperative day 5 followed by prednisone 5 mg/day PO. The prednisone was then tapered by 5 mg/month until discontinuation after the month 3 post‐transplant
Outcomes	Outcomes reported: mortality at maximal follow‐up, serious adverse events (number of events), liver transplantation at maximal follow‐up, graft rejection (any) Follow‐up (months): 12
Notes	Source of funding: not stated Trial name/trial registry number: not stated Attempts were made to contact the authors in August 2019.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: this information was not available
Allocation concealment (selection bias)	Unclear risk	Comment: this information was not available
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: this information was not available
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: this information was not available
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: there were post‐randomisation dropouts. It was not clear whether these could be related to the interventions
Selective reporting (reporting bias)	Low risk	Comment: no pre‐published protocol was available, but the authors reported on mortality, graft loss, and adverse events
Other bias	High risk	Comment: the regimen for tacrolimus was different between the groups

Abbreviations:

HCC: hepatocellular carcinoma

HCV: Hepatitis C virus

OLT: orthotopic liver transplantation

RNA: ribonucleic acid